SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Dishman Carbogen Amcis gains after its arm enters into co- investment agreement with European customers

26 Aug 2021 Evaluate

Dishman Carbogen Amcis is currently trading at Rs. 184.70, up by 2.65 points or 1.46% from its previous closing of Rs. 182.05 on the BSE.

The scrip opened at Rs. 185.90 and has touched a high and low of Rs. 186.60 and Rs. 181.60 respectively. So far 27944 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 235.00 on 20-Jul-2021 and a 52 week low of Rs. 102.55 on 25-Mar-2021.

Last one week high and low of the scrip stood at Rs. 190.10 and Rs. 167.80 respectively. The current market cap of the company is Rs. 2894.22 crore.

The promoters holding in the company stood at 59.32%, while Institutions and Non-Institutions held 12.66% and 28.01% respectively.

Dishman Carbogen Amcis’ wholly owned subsidiary -- Carbogen Amcis AG has entered into co- investment agreement with one of its key European customers. The agreement provides for additional process capabilities and capacities to facilitate the manufacture of the customer’s commercial product and follows a previous investment of Swiss franc 6 million.

The co-investment totals Swiss franc 4 million and will be focussed on expanding capacities to support the market introduction of the customer’s lead compound. The investment at the Carbogen Amcis AG. Neuland location includes the addition of a medium pressure chromatography column (200L), a preparative 20 cm HPLC system and short path distillation equipment.

Dishman Carbogen Amcis provides innovative solutions for the development and supply of drug substances and drug products to the pharmaceutical and biopharmaceutical industries.

Dishman Carbogen Amc Share Price

168.60 -2.00 (-1.17%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×